Targeting WDR5: A WINning Anti-Cancer Strategy?
WDR5 is a component of multiple epigenetic regulatory complexes, including the mixed lineage leukemia (MLL)/SET complexes that deposit histone H3 lysine 4 methylation. Inhibitors of an arginine-binding cavity in WDR5, known as the W DR5- in teraction (WIN) site, have been proposed to selectively kil...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-07-01
|
| Series: | Epigenetics Insights |
| Online Access: | https://doi.org/10.1177/2516865719865282 |